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Introduction
Influenza is a viral disease that routinely causes significant mor-
bidity and mortality. Influenza pandemics have been responsible 
for the deaths of tens of millions of people in the last century 
alone. Science has been desperately searching for any agent to 
mitigate the effects of this infectious disease. 
Tamiflu (a neuraminidase inhibitor) was brought to market in 
the last 20 years with great fanfare and hope.  During the 2009 
influenza pandemic government agencies and hospitals spent 
billions of dollars stockpiling the Tamiflu. It was widely touted 
by health professionals and the media as an effective “silver 
bullet” for the disease. In 2009 The Cochrane Report created 
a tremendous uproar with a British Medical Journal (BMJ) re-
port that concluded that Tamiflu was not effective. Despite the 
controversy, Tamiflu continues to be recommended for use at 
clinics and hospitals as first line defense for treatment as well as 
prophylaxis (Zachary 2015).
Like any medication, use of Tamiflu involves financial and other 
costs i.e. side effects. Given that it is not a benign drug, it be-
hooves us to explore the controversy in detail.
Methods
The information for this paper was obtained from many on-
line resources.  Many of the databases and journals used were 
accessed through the Touro library database and PubMed.gov. 
Much of the background information and pictures were ac-
cessed through Dr. Vincent Racaniello’s (College of Physicians 
and Surgeons of Columbia University) “Virology 101” blog.
Background
Influenza is a viral infection that attacks the respiratory system 
(the nose, throat and lungs). It is caused by one of the three 
types of influenza viruses A,B and C. Influenza viruses can be 
spread by airborne droplets(aerosols) person-to-person con-
tact, or contact with contaminated items (fomites). Airborne 
spread appears to be the most important mechanism. A single 
sneeze can generate up to 20,000 virus containing aerosol par-
ticles. Aerosolized particles produced by these activities are of 
different sizes. The largest droplets fall to the ground within a 
few meters and will transmit an infection only to those in the 
immediate vicinity. Smaller droplets can travel long distances 
determined by their size. 
Onset of symptoms ranges from 1 to 4 days with an average 
of about 48 hours. Symptoms include sudden onset of chills, 
fever, cough, and generalized aches and pains. Severe Headache 
is common. In mild cases, many symptoms are like those of a 
common cold e.g. sore throat, runny nose, and mild conjuncti-
vitis may also occur. After 2 to 3 days, acute symptoms rapidly 
subside, although fever may last up to 5 days. Cough, weakness, 
sweating, and fatigue may persist for several days or occasionally 
for weeks.
Influenza-related pneumonia is an important cause of increased 
morbidity or mortality in high-risk patients. Encephalitis, myo-
carditis, and myoglobinuria, sometimes with renal failure, de-
velop infrequently after influenza A or B infection. Patients at 
higher risk are those with: underlying illness, acute respiratory 
distress syndrome, primary influenza pneumonia, or secondary 
bacterial pneumonia .These include: Children under the age of 
4 years; adults over the age of 65 years; people with chronic 
medical disorders (e.g., cardiopulmonary disease, diabetes mel-
litus, renal or hepatic insufficiency, hemoglobinopathies, immu-
odeficiency); women in the 2nd or 3rd trimester of pregnancy 
and patients with disorders that impair handling of respiratory 
secretions (e.g., cognitive dysfunction, neuromuscular disorders, 
stroke, seizure disorders).
Aside from the use of antivirals such as Tamiflu treatment is 
symptomatic. This includes rest, hydration, and antipyretics 
as needed. Appropriate antibiotics are necessary for treating 
complicating bacterial infections. Antiviral drugs given with-
in 1 to 2 days of symptom onset may decrease the duration 
of fever, severity of symptoms, and time to return to normal 
activity. The two main drug types are the neuraminidase inhib-
itors Oseltamivir and Zanamivir, and the adamantane drugs, 
Amantadine and Rimantadine. Neuraminidase inhibitors inter-
fere with release of influenza virus from infected cells thereby 
halting the spread of infection. These will be discussed at length 
in this paper. Adamantanes block the M2 ion channel thereby 
interfering with viral uncoating inside the cell. They are effective 
only against influenza A viruses (influenza B viruses lack the M2 
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protein). Choice of antiviral drug is complicated by resistance 
of different influenza types and subtypes to different drugs 
(Pringle, 2014).
The influenza virus is unique in that it completely experienc-
es changes in the characteristic of the antigens on its surface. 
Typically, small changes occur from one year to the next. This 
is known as “antigenic drift”. Less frequently, there are signifi-
cant changes in the surface antigens. This is known as “antigenic 
shift.” Hosts who have been previously exposed to influenza 
generally have some residual immunity against viruses that have 
drifted antigenically. In contrast, there is little/no preexisting im-
munity against viruses that have shifted antigenically. The former 
is responsible for epidemics which tend to be milder in severity. 
The latter situation results in influenza pandemics, with high 
mortality e.g. The Spanish influenza of 1918 is thought to have 
caused 30-50 million deaths worldwide. 
Influenza Type A can cause pandemics and epidemics and is 
our main concern. Type B can only cause epidemics. Type C can 
cause mild illness but does not cause pandemics nor epidemics. 
Influenza is often confused with “Influenza-like- illness” which 
may be caused by other factors but has similar symptoms.
Influenza is most common in the winter months. This is because 
the winter conditions are optimal for the spread of influenza. 
The transmission of infection is most effective at a humidity 
level of 20-35 degrees and colder temperatures. At these con-
ditions virion particles are more stable and can travel further 
distances in droplets (Mubareka et al., 2009). Increasing levels of 
humidity of indoor air during the winter may be an effective way 
of decreasing the spread of influenza.
Pathophysiology
Influenza types
As noted above There are three types of Influenza A, B and C. 
Type A and type B cause the same spectrums of disease but 
type B can only infect humans and seals and therefore limits the 
reassortments in contrast to type A which has numerous hosts 
and numerous reassortments.
Influenza A Subtypes
Type A has 3 different membrane proteins, surface proteins 
hemagglutinin (HA), neuraminidase (NA). Matrix protein 2 
(M2) traverses the membrane. As shown in figure 1. (Type B has 
the HA and NA proteins but does not have the M2 protein). 
(Tscherne and Garcia-Satre, 2011). The subtypes of influenza A 
are classified based on the HA and NA proteins. There are 18 
HA types and 11 NA types. This means there are 198 possible 
combinations. The nomenclature of the virus describes the HA 
and NA subtypes for example a virus with HA type 11 and NA 
type 7 is called Influenza H11N7. Only a few types of influenza 
are pathogenic to humans. This depends on their ability to bind 
to Human sialic acid, as discussed later.
Antigenic drifts are minor mutations in preexisting HA and NA 
combinations resulting in new strains. This decreases the effec-
tiveness of antibodies to the Influenza. Antigenic Shifts are new 
combinations of HA and NA proteins. Such as a change from 
H1N1 to H1N2. Antibodies produced against previous influenza 
strains are generally ineffective, thereby increasing its ability to 
infect and cause illness. These shifts often occur when two dif-
ferent influenza types infect one cell. When the viruses replicate 
the RNA can then combine and form a new “reassortant” type 
(see picture 3 below (Ranciello, 2013)).
HA (bl ue), NA (red), and M2 (purple) proteins 
(Ranciello 2013)
Figure 1
Influenza reassortment (Ranciello, 2013)
Figure 2 
65
Is Tamiflu Effective in Influenza Treatment?
NA Structure
NA is a tetramer of four identical polypeptides each contain-
ing approximately 470 Amino Acids. It has four sections: A cy-
toplasmic sequence, a transmembrane sequence, a stalk and a 
globular head. There are two phylogenetic groups of NA, NA 
group 1 and NA group 2. Group 1 contains N1, N4, N5 and 
N8. Group 2 contains N2, N3, N6, N7 and N9. Group 1 has 
an additional cavity “150 loop” that is not present in group 
2(Air, 2012).
Cell Invasion
Animal respiratory cell membranes contain Sialic acid mole-
cules. These molecules are the binding site receptors of the 
influenza virus. (Gamblin, and Skehel, 2010). When viral HA 
proteins bind to sialic acid receptors on the host cells a se-
quence of events is set in motion resulting in the virus entering 
the cell.
Types of Sialic Acid
Sialic acid is a glycoprotein. It is typically linked to a galactose 
molecule. As stated, Sialic acid is linked to galactose. There are 
2 main types of such linkages: 1. Alpha2, 3 linkage (pictured 
above), in which the carbon 2 of the acid is linked to the car-
bon 3 of galactose. 2. Alpha 2, 6 linkage, in which the carbon2 
of the acid is linked to carbon 6 of galactose. Humans primar-
ily have a2, 6 receptors. This means that viruses targeting this 
structure are more likely to infect these cells. The results of 
studies of early influenza virus isolates from the 1918, 1957, 
and 1968 pandemics suggest that these viruses preferentially 
recognized alpha (2, 6) linked sialic acids. In contrast, viruses 
targeting the a2, 3-linked structure are not very pathogenic 
for humans. In humans, these linkages are only found in ciliated 
epithelial cells, which are a minor population within the human 
respiratory tract. Nevertheless, these are the preferred recep-
tors for the avian flu (Matrosovich et al., 2000).
Mechanism of infection
First the viral HA protein binds to the sialic acid receptors 
on the cell membrane. The virus is then engulfed by the cell 
through endocytosis. This causes the pH of the endosomal ves-
icle to drop to 5 which activates a conformation change on the 
HA protein which exposes a fusion peptide. The fusion peptide 
enables the viral envelope to fuse with the vesicle membrane 
wall. The viral RNA is then released into the cytoplasm. Viral 
RNA travels to the nucleus to initiate protein synthesis and 
assemble new viruses. The newly formed viruses travel back to 
the cell membrane. The virus interacts with the cell membrane 
causing it to bud off. The virus is released to infect other cells. 
The mechanism of the virus leaving involves a potential problem. 
One would expect the viral HA protein to bind to the sialic acid 
receptors on the cell membrane as it leaves. This would result 
in the virus becoming trapped on the host cell. This is prevented 
by the NA protein which cleaves the sialic acid to allow the 
virus to escape (Wagner et al, 2002). NA also cleaves sialic acid 
molecules in mucus in the human respiratory tract (Cohen, et 
al., 2013). This increases viral infectivity.
Neuraminidase inhibitor drugs
In order to prevent viral infection the NA protein has been 
exploited by developing drugs that act as sialic acid analogs 
which bind to the NA active site. These are called NA inhibitors. 
These drugs disable the NA protein from cleaving sialic acid, 
leaving the virus trapped on the cell (Russel et al., 2006).Tamiflu 
(Oseltamivir) and Relenza (Zanamivir) are the two drugs which 
dominate the market. These have been stockpiled by govern-
ments and public health agencies (Jefferson et al., 2009) for the 
treatment of Flu and are recommended by the CDC.
Oseltamivir resistant strains
There have emerged strains of flu that are resistant to oseltami-
vir.  This is due to a point mutation of histidine being switched 
for tyrosine (H274Y) in NA. This leads to decreased binding of 
the drug. Nevertheless this change is also detrimental for the 
virus as it leads to a decrease of surface NA reducing the virus 
replicating abilities and infectivity.
During the 2008-09 flu season oseltamivir resistant influenza 
H1N1 viruses with the H274Y change became more prevalent, 
and within a year they were found in most seasonal isolates. Two 
amino acid changes were identified that even in the presence 
of H274Y restore surface levels of NA. These are V234M and 
R222Q. These secondary mutations seem to balance the dele-
terious effects of the H274Y mutation, thus enabling it to spread 
(Bloom et al., 2010). 
Discussion- The Tamiflu Controversy
Cochrane Report
At the height of the 2009 H1N1 influenza pandemic, the British 
Medical Journal (BMJ) released a Cochrane update (of a 2005 
Cochrane meta-review) which shook the medical world. The 
report cast serious doubt on the usefulness of neuraminidase 
inhibitors (Nis) in influenza. Specifically concluding that, at best, 
NIs reduce symptoms by approximately one day- a moderate 
benefit. 
They reviewed 1416 titles for neuraminidase inhibitors mostly 
on oseltamivir. They discarded all but 20 due to various prob-
lems. These included, variously, insufficient information, inac-
cessibility to data, poor description of methods, and issues of 
reliability. For example, some studies used a mixed population 
of healthy adults and those with comorbid complications. This 
66
Eliyakim Hershkop
meant the studies weren’t effective in properly determining 
outcome in healthy populations. They noted that, even this data 
may not be accurate as up to 80 percent of the studies may have 
not been “pure” influenza, rather “influenza like illness”. This is 
because influenza was unconfirmed by laboratory tests. 
Most importantly, according to Cochrane, there is insufficient 
data as to whether NIs are effective in reducing complications 
of lower respiratory tract infection as indicated by antibiotic 
use or hospital admissions. They also note that there is a sig-
nificant risk of toxicity, especially of psychosis, in prophylactic 
treatment. They concluded “because of the moderate effective-
ness of neuraminidase inhibitors, we believe they should not be 
used in routine control of seasonal influenza.”
Kaiser et al (2003)published a meta-analysis of 10 studies of 
oseltamivir. They concluded that Oseltamivir was effective in re-
ducing lower respiratory tract infections (LRTIs). The Cochrane 
2005 report, which relied on this study also concluded that it 
was effective in reducing LRTIs. 
Hayashi (Jefferson, et al, 2009) pointed out that the 2005 
Cochrane report was flawed in that they didn’t actually re-
view the data of the individual studies themselves. In addition, 
he questioned the reliability of the Kaiser report as only 2 of 
these studies were actually published in peer reviewed journals 
(JAMA and Lancet).  The other eight were not and were not 
available for review. He also notes a conflict of interest in that 
the authors of the Kaiser report included four employees and 
one paid consultant of F. Hoffman-La Roche (the manufacturer 
of oseltamivir). Hayashi also noted that in the two published 
studies, there was no significant difference between Oseltamivir 
and placebo in the incidence of LRTIs. He suggests that the only 
way to rely on the report is by a rigid appraisal of the other 
eight trials-which were not released by the drug company La 
Roche.
Cochrane was unable to obtain the data of the 8 unpublished 
studies for further  analysis. This led Cochrane to conclude 
in 2009 that “paucity of good data has undermined previous 
findings for oseltamivir’s prevention of complications from in-
fluenza. Independent randomized trials to resolve these uncer-
tainties are needed.” The question of a publication bias was also 
raised by Cochrane due to the fact that these results weren’t 
published.
Doshi (2009), (a Cochrane author) goes so far as to suggest that os-
eltamivir is no better than NSAIDs, such as aspirin, in the treatment 
of influenza. He also notes the numerous contradictory reports in 
the clinical studies on the effectiveness of oseltamivir which casts 
doubts upon the reliability of the methods and information used 
to generate these reports. He criticizes the fact that government 
organizations have spent so much money on a drug before ascer-
taining the reliability of the data of its effectiveness.  He notes that 
the Centers for Dis¬ease Control and Prevention (CDC) based 
their recommendations on the problematic Kaiser report.
The US government also partly based its national pandemic pre-
paredness strategy on similar assumptions. As a result billions of 
dollars were spent building drug stockpiles, and oseltamivir was 
elevated to the status of a public health drug.
In 2014, Cochrane (published in BMJ 2014) released an update 
of a 5 year campaign it launched against Roche to obtain all the 
clinical study reports (CSRs)- which are extensive summaries of 
RCTs, on Tamiflu. Cochrane managed to pressure Roche into 
releasing all their data. They note that this is the first time all 
clinical study reports of trials in a manufacturer’s program have 
been made available to readers without any restriction. The im-
portance of this is the ability of researchers to assess the clinical 
trials for reliability, adherence to protocol, clarity of definitions 
and avoided reliance on conclusions of researchers who may 
have published biased material. It also allows for considerable 
more information on potential harms.
Cochrane notes that many discrepancies, problems and biases 
have been found in these trials. These include:  Lack of clear defi-
nitions. For example there are eight definitions for laboratory 
confirmed influenza and no clear definition for influenza-like ill-
ness. Lack of reliability of the placebo. In many cases the placebo 
capsule had a different colored cap than that of the active cap-
sule. This was not remarked on in the report. Many of the pla-
cebo capsules in oseltamivir trials contained dehydrocholic acid 
and dibasic calcium phosphate dihydrate. Both can cause gastro-
intestinal symptoms. Although the substances seemed to be in 
low doses, no discussion of their potential effects in people with 
fever was reported. Missing documents. This includes missing 
study protocols and amendments, study manuals of procedures 
and minutes of safety data monitoring committee meetings. 
Ghost authorship and lack of accountability. Authorship and ac-
countability for the writing of many of the clinical study reports 
remains unclear. Some names on studies were redacted and no 
one seemed to claim responsibility for assembling and writing 
the reports. Missing data on duration and durability of symptom 
relief. Data on relapse after the five day treatment period were 
not reported in the clinical study reports. 
There was also a mix-up with follow-up cards in a few of the 
trials which was not even reported in CSRs and only came to 
light from the FDA Summary Basis of Approval papers. There 
is ambiguity as to whether treatment of the flu shown through 
reduction of antibody titers was due to effectiveness of the viral 
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fighting activity of the drug or the immunosuppressant activity 
of the drug.
Cochrane 2014 concludes that oseltamivir is helpful for prophy-
laxis and modestly helpful in treatment (though they downplay 
its usefulness). In contrast to the assertion of various orga-
nizations Cochrane concludes that there is little evidence of 
significant benefits with regards to complications caused by 
influenza and viral transmission. Due to the above as well as 
the side effects, oseltamivir should be used cautiously. Due to all 
the discrepancies and poor quality of the studies, they question 
governmental sole reliance on this data to stockpile oseltamivir, 
its inclusion on the WHO list of essential drugs, and its use 
in clinical practice as an anti-influenza drug. This is especially 
true due to lack of sizeable benefits, and concerns of toxicity 
(Jefferson et al, 2014).
Cochrane study results
For Adults in Treatment trials: oseltamivir reduced the time to 
first alleviation of symptoms by 16.8 hours-from seven days to 
6.3 days. In treatment trials there was no difference in admissions 
to hospital. 
For Adults in prophylaxis pre-exposure: oseltamivir reduced 
symptomatic influenza in participants by 55%. There was no sig-
nificant effect on asymptomatic influenza (increase in antibody 
titers without symptoms). In post-exposure there are two com-
ponents to interrupting transmissions of the virus. The reduction 
of viral spreading from nasal shedding and the prevention of 
onset of influenza in contacts.
Roche claims that it is effective, but there were serious flaws 
in the methods of the studies. This includes giving paracetamol 
which may have reduced viral shedding, and not checking anti-
bodies in participants with potentially asymptomatic influenza. 
This leads to the conclusion that there is “no evidence of a re-
duction in transmission.” 
It is important to note that these studies specifically influenced 
WHO’s policy of recommending this drug. 
Harms for Treatment: increased the risk of nausea (risk differ-
ence 3.66%, 0.90% to 7.39%; number needed to treat to harm 
(NNTH) 28.) and vomiting (4.56%, 2.39% to 7.58%; 22, 14 to 42).
For Prophylaxis: oseltamivir increased the risk of psychiatric ad-
verse events during the combined “on-treatment” and “off-treat-
ment” periods (risk difference 1.06%, 0.07% to 2.76%; NNTH 94, 
36 to 1538) and there was a dose-response effect on psychiatric 
events in two “pivotal” treatment trials of oseltamivir, at 75 mg 
(standard dose) and150 mg (high dose) twice daily (P=0.038).
Oseltamivir increased the risk of headaches on-treatment (risk 
difference3.15%, 0.88% to 5.78%; NNTH 32, 18 to 115).It in-
creased renal events with treatment (0.67%,−0.01% to 2.93%), 
and increased nausea while receiving treatment (4.15%, 0.86% to 
9.51%; NNTH 25, 11 to 116).
For child treatment it reduced influenza for otherwise healthy 
children by 12 to 47 hours with a mean difference of 29 hours. 
There was no effect in children with asthma. There was no signifi-
cant difference in admissions to hospital. There was no significant 
effect on bronchitis, otitis media, sinusitis unverified pneumonia 
or any complication classified as serious or that led to study 
withdrawal. There was no significant difference in prophylaxis. 
In treatment of children, oseltamivir induced vomiting (5.34%, 
1.75% to 10.29%; 19, 10 to 57).
Cochrane’s call to governments
Compared with a placebo, taking Tamiflu led to a quicker allevia-
tion of influenza-like symptoms of just half a day (from 7 days to 
6.3 days) in adults, but the effect in children was more uncertain. 
There was no evidence of a reduction in hospitalizations or se-
rious influenza complications; confirmed pneumonia, bronchitis, 
sinusitis or ear infection in either adults or children. Although 
when used as a preventative treatment, the drug can reduce the 
risk of people suffering symptomatic influenza, it is unproven that 
it can stop people carrying the influenza virus from spreading it 
to others.  
Evidence from treatment trials confirms increased risk of suf-
fering from nausea and vomiting. And when Tamiflu was used in 
prevention trials, there was an increased risk of headaches, psy-
chiatric disturbances, and renal events. 
Evidence also suggests that Tamiflu prevented some people from pro-
ducing sufficient numbers of their own antibodies to fight infection.
Claims about the effectiveness of Tamiflu against complications 
were a key factor in decisions made by governments around the 
world to stockpile these drugs in case of a pandemic. The US 
has spent more than $1.3 billion buying a strategic reserve of 
antivirals, while in the UK the government has spent almost £424 
million  for a stockpile of about 40 million doses*.
It was initially believed that it would reduce hospital admissions 
and complications of influenza, such as pneumonia, during influ-
enza pandemics. However, the original evidence presented to 
government agencies around the world was incomplete.
Along with the evidence of harms from the medication, it raises 
the question of whether global stockpiling of the drugs is still jus-
tifiable given the lack of reliable evidence to support the original 
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claims of its benefits. The BMJ and Cochrane issued a joint call to 
government and health policy decision makers the world over 
asking, in light of the latest findings from the Cochrane Review, 
would you make the same recommendations today, choosing to 
stockpile Tamiflu? (Breeze and Burns 2014).
Criticisms against the Cochrane reports
There are many that criticized the BMJ/Cochrane reports. The 
study was done in collaboration with channel 4 TV station in Britain. 
This may have led to a conflict of interests in overdramatizing a 
story for viewers. As Revere notes (Revere 2009) “Doing this in 
tandem with a media outlet whose objectives are not science but 
snagging viewers is unseemly at best and borders on the unethical”.
An article in Nature (Noorden 2014) notes that it seems as 
if Cochrane, in their overzealousness to confront the big 
Pharmaceutical agencies have been ”cherry-picking” the results 
to make them look worse for antivirals. Some of their statements 
have contributed to media misinterpretation that the drugs are 
‘ineffective’ or ‘useless’.” For example: Cochrane writes ” (os-
eltamivir) reduces symptoms of influenza by half a day” instead 
of the more precisely stating 18 hours for adults and 29 hours 
in children. In the 2009 report they also neglect to mention the 
prophylactic benefits. The Cochrane article obscures the thera-
peutic effect on decreased risk of diarrhea and cardiac system 
events by sandwiching them among the harms of the drug. A 
Cochrane author takes the extreme approach-not supported 
by evidence- of suggesting that Oseltamivir is no more effective 
than paracetamol.
It is important to note that Cochrane hasn’t shown that antivi-
rals didn’t work for healthy people who got flu and were given 
a neuraminidase inhibitor to avoid more serious complications 
like pneumonia. It just alleged there was no “Cochrane-required-
level-of-evidence” that they did prevent complications.
Cochrane only uses Randomized Controlled Trials (RCTs). 
These are studies in which volunteers are randomly assigned to 
get a treatment or a placebo and are considered the gold stan-
dard of evidence. Observational Studies that observe outcomes 
in people who receive a treatment don’t make the cut because 
they are “unreliable for establishing treatment effects”. However, 
often the observational studies are better at concluding the ac-
tual facts on the ground as opposed to the theory. For example, 
an observational study (Muthuri, 2014) of 30,000 people hos-
pitalized during the 2009–10 swine-flu pandemic reported that 
neuraminidase inhibitors reduced mortality by 25%.
Although RCTs are considered the gold standard in of establish-
ing effectiveness of a drug, they lack sufficient statistical power to 
allow reliable conclusions to be drawn about the effects on flu 
complications and hospitalizations- which are the key outcomes 
of interest during a flu pandemic. This is especially true noting 
that these small clinical trials were carried out to gain regulatory 
approval for Tamiflu as treatment and prophylaxis for seasonal flu. 
The trials were not designed to test for the severe outcomes that 
are most relevant to pandemics.
Additionally, The Metro (Branswell 2009) notes, sometimes 
it isn’t possible to conduct randomized controlled trials. 
Sometimes observational data is the best evidence available.
For instance, it’s unlikely any researchers could get permission 
to test Tamiflu against a placebo in people severely ill with 
H1N1. It would be considered unethical to withhold the drug 
from severely ill H1N1 patients if observational data suggested 
the drug might help.
Researchers worry that the Cochranes recommendation “we 
believe they should not be used in routine control of seasonal 
influenza” and the ensuing media storm of overly negative pub-
licity risks undermining public confidence in this class of drug 
which will increase illness. Tamiflu is prescribed as the main 
treatment for serious cases of flu. Many experts say based on 
the observational data that these drugs work and have benefi-
cial effects on severity of illness and preventing death. They are 
worried that we risk losing one of the few weapons we have. 
This is especially true based on the timing of the release and the 
lack of conclusive evidence that it doesn’t work. “So here we 
are in the middle of a pandemic and the Cochrane folks, aided 
and abetted by the BMJ and television producers, are saying, 
“How do you know for sure that they will prevent pneumonia 
in an otherwise healthy person who gets flu?” There is evidence 
about this, even if the Cochrane zealots don’t recognize it”.
Evidence supporting the efficacy of Oseltamivir
It is hard to say that Oseltamivir is completely ineffective. One 
of the first human studies on the effectiveness of Tamiflu was 
published approximately fifteen years ago. In a 1999 study 
(Hayden et al) 117 healthy adult volunteers were inoculated 
with the influenza A virus. Two studies were conducted, one on 
prophylaxis where volunteers were given the drug 26 hours be-
fore inoculation and one on therapeutic treatment where they 
were given the drug 26 hours after inoculation. Treatment was 
continued for 5 days. In these trials, prophylaxis and early treat-
ment with oral oseltamivir were both associated with significant 
antiviral and clinical benefits in experimental human influenza.
Prophylactic
Among the 12 evaluable placebo recipients, 8 (67%) had labora-
tory-confirmed infection and 6 (50%) had recovery of the virus 
from nasal washings. In contrast, of the 21 receiving oseltamivir 
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only 8 (38%) had laboratory confirmed infection and none of 
the 21 evaluable oseltamivir recipients had virus isolated.
The total symptom score area under the curve value was lower in 
the combined oseltamivir groups (n=21) compared with placebo 
(n=12); P=.02. Fourteen symptoms related to influenza were in-
cluded in the score.
Therapeutic
Of the 69 with laboratory confirmed illness At 24 and 36 hours 
after initiating treatment, the median time to cessation of viral 
shedding was reduced from 107 hours in the placebo group to 58 
hours in the combined oseltamivir group as shown in the graph. 
No virus was detected by 60 hours after infection. Effect of Oral 
Oseltamivir Treatment on Illness Following Experimental Influenza 
A/Texas/36/91(H1N1) Infection The total symptom score area 
under the curve value was lower in the combined oseltamivir groups 
(n=56) compared with placebo (n=13);
The total symptom score area under the curve value was lower in 
the combined oseltamivir groups (n=56) compared with placebo 
(n=13);
Dobson et al, 2015
In 2015 the Lancet published a study by Dobson et al. which shows 
that oseltamivir in adults with influenza accelerates time to clinical 
symptom alleviation, reduces risk of lower respiratory tract compli-
cations, and admittance to hospital.
The Cochrane reviews were based on meta-analysis of clinical trial 
study reports alone and not on individual patient data. In the Lancet 
study, Dobson et al did a meta-analysis of all available randomized 
treatment trials of oseltamivir-which includes both published and un-
published data (thereby overcoming previous concerns regarding po-
tential publication bias). This analysis is first of its kind that reviewed 
individual patient data.
Nine trial studies were done between 1997 and 2001 involving 4328 
participants. Participants were labeled as laboratory confirmed in-
fluenza-infected (“intention to treat infected”) and Influenza-like 
(“intention to treat non- infected”).   Participants were within 36 
hours of feeling unwell- with a fever and at least two other influenza 
symptoms. They received 5 day regimens of Tamiflu with a 21 day 
follow up.
Limitations of these studies are that they weren’t set up to test for 
relieving of respiratory complications As such, specific diagnostic 
tests were not used. Instead, in order to enhance reliable reporting 
of complications they incorporated “antibiotic use” in the definition 
of LTRIs. These tests were also not set up to determine prophylactic 
effects.
Effectiveness
Included are data from nine trials including 4328 patients. In 
the Influenza confirmed population (intention-to-treat infected 
population), 
Alleviation of all symptoms for oseltamivir versus placebo recipi-
ents-21% shorter time of 25·2 h,
(The median times to alleviation were 97·5 h for oseltamivir and 
122·7 h for placebo)
An estimated 44% reduction in risk lower respiratory tract compli-
cations requiring antibiotics more than 48 h after receiving oseltami-
vir (65 of 1544 participants given oseltamivir and110 of 1263 partici-
pants given placebo. Components were 56 versus 87 bronchitis, nine 
versus 21 pneumonia, and one versus four lower respiratory tract 
infections, respectively)
An estimated 63% risk reduction of admittances to hospital for any 
cause In the intention-to-treat (nine of 1591 participants had to be 
admitted to hospital for any cause versus 22 of 1302 participants 
given placebo). Participants given Oseltamivir had significantly less 
diarrhea, infections and infestations, and respiratory, thoracic and 
mediastinal disorders and fewer cardiac disorders.  Regarding safe-
ty, increased the risk of nausea (9·9% oseltamivir vs 6·2% placebo), 
increased vomiting (8·0% oseltamivir vs3·3% placebo). No recorded 
effect on neurological or psychiatric disorders (although slightly high-
er with 150 mg). No serious adverse events.
Non-confirmed influenza (intention-to-treat non- infected 
population)
Oseltamivir was ineffective in non-confirmed influenza. This is 
consistent with the fact that Oseltamivir is an anti-viral. In some 
studies some researchers haven’t distinguished between con-
firmed and non-confirmed influenza population. This will skew 
the results of efficacy of the drug being that it is not meant to 
treat non-confirmed influenza. Nevertheless, these results will 
more clearly resemble the effectiveness in real world situations 
where there is mix of these populations.
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CDC rejection of Cochrane Report
The CDC (CDC 2015) continues to promote antivirals such as 
Oseltamivir for treatment of the flu. The CDC promotes the 
“Take 3” campaign to fight the flu. Step 1 is to get vaccinated. 
Step 2 is taking preventative action to stop the spread of germs. 
Step 3 of the campaign encourages people to “take flu antiviral 
drugs if your doctor prescribes them.” 
In CDC (2014) an article entitled ““Have You Heard?  CDC 
Recommendations for Influenza Antiviral Medications Remain 
Unchanged.” The CDC addresses their recommendations and 
the Cochrane’s criticism. Based on the observational studies 
published, the CDC says “treatment with a neuraminidase in-
hibitor antiviral drug was associated with a 25% reduction in the 
likelihood of death compared to no antiviral treatment. Early 
treatment with neuraminidase inhibitor antiviral drugs (i.e., 
within 48 hours of development of influenza illness) halved the 
risk of death compared to no antiviral treatment. This confirms 
findings from previous observational studies in hospitalized in-
fluenza patients that the clinical benefit of neuraminidase inhibi-
tor antiviral treatment is greatest when started within two days 
of influenza illness onset.”  
 The CDC states that their disregard for the Cochrane findings 
is because Cochrane did not consider any data from observa-
tional studies of oral oseltamivir. CDC adds that observational 
studies of antiviral treatment of seasonal influenza or influenza 
A (H1N1) pdm09 (2009 H1N1) have been conducted among 
hospitalized patients, including critically ill children and adults. 
Theses have consistently found that early oseltamivir treatment 
of influenza patients reduces the duration of hospitalization and 
risk of severe outcomes such as intensive care unit admission 
or death. CDC states that Cochrane RCT reviews of data on 
outpatients with clinically mild influenza-like illness is limited in 
by the narrow scope of participants. It is statistically underpow-
ered and not designed to assess the effects of the medications 
on more severe influenza illness outcomes, such as hospital-
izations, intensive care unit admissions, or deaths. RCT data 
is unavailable for those at highest risk for developing severe 
complications from influenza: hospitalized patients with severe 
influenza illness, the elderly, young children, pregnant women, 
and persons with underlying medical conditions such as chron-
ic obstructive pulmonary disease (COPD), asthma, congestive 
heart failure and diabetes. 
They conclude “available evidence for seasonal influenza and 
2009 pandemic H1N1 virus infections consistently indicates 
that antiviral treatment, when initiated as soon as possible, can 
have clinical and public health benefits in reducing severe out-
comes of influenza. Therefore, neuraminidase inhibitor antiviral 
medications continue to be recommended for treatment of 
influenza.”
BMJ/Cochrane response to CDC and Lancet
In a response article written by the BMJ’s Jeanne Lenzer “Why 
aren’t the US Centers for Disease Control and Food and Drug 
Administration speaking with one voice on flu? ” (BMJ 2015) 
Lenzer raises allegations regarding the reliability of CDC. She ac-
cusing them of being “more emotional than scientific” and notes 
that they are at odds with the FDA Who have said oseltamivir “has 
not been proven to have a positive impact on the potential conse-
quences (such as hospitalizations, mortality, or economic impact) 
of seasonal, avian, or pandemic influenza.” She considers the CDC’s 
reliance on the Lancet review as unreliable. This is because the au-
thors have not made their study protocol available for critique nor 
have they released an appraisal of the methodological quality of 
each study.  She concludes by raising the concerns that the policies 
of the CDC and Lancet review have been influenced by funding 
from the Pharmaceutical companies. The CDC Foundation con-
firmed to The BMJ that the CDC received a directed donation 
from Roche for the campaign, stating, “Roche provided a grant of 
$198 000 to CDC Foundation [which] has an administrative fee 
of 13.5%, so $174 800 was provided to [the CDC to] support 
qualitative research into influenza prevention and treatment mes-
saging.” The CDC Foundation also receives funding from the phar-
maceutical industry. A spokesperson said that over the past three 
years the foundation has received an average of around $6.3m 
annually from the industry, 21% of the foundation’s overall funding. 
Some of the companies who have provided funds include Gilead, 
which holds the patent on oseltamivir, as well as Genentech and 
Roche, the drug’s manufacturers. This greatly discredits the CDC’s 
credibility as a nonbiased party.
The Lancet’s Funding
The Lancet study itself was conducted through MUGAS which 
was funded by an open grant from Roche- as the study noted. 
Lancet asserts that neither they nor the study itself were influ-
enced in any way by Roche. Additionally, neither MUGAS nor 
Roche saw the results of the study before publication.
Also two of the researchers note that they have had ties in the 
past to Roche. A third researcher, Stuart Pocock didn’t list any 
conflict of interest on the research paper, but revealed to The 
BMJ that he has received funding from several drug companies for 
cardiovascular research, including Gilead and Genentech, but that 
none of his funding was related to the study of antivirals for flu.
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Paul Roblin in his BMJ blog notes Although the name Multiparty 
Group for Advice in Science ( MUGAS) might lead you to imag-
ine an independent body bringing together representatives of a 
number of organizations to consider a range of issues, MUGAS is 
funded by Roche and is led by four scientists, three of whom are 
advisers to Roche. It appears to have been set up specifically as 
part of the attempt to counter the Cochrane’s criticisms. He also 
notes that there is a complex set of inter-related organizations 
that supported the Lancet study and receive funding from Roche 
and Gilead. Also, one the Lancet authors and MUGAS have many 
more connections to the CDC, Roche and Gilead than they dis-
closed. One of the researchers for the Lancet article, Professor 
Richard J Whitley joined Gilead’s board of directors in 2008 and 
works with/for the CDC. 
Conclusion
All parties agree about the following: Oseltamivir is effective 
in reducing symptoms by at least 16 hours. Oseltamivir works 
reasonably well for prophylaxis. Oseltamivir has significant side 
effects including psychosis in prophylactic patients.
The main debate is whether it reduces secondary complications, 
hospitalizations and spread of disease. The debate also centers 
on whether it is justifiable to prescribe oseltamivir in the face of 
significant side effects.  Also questioned is the wisdom of govern-
mental stockpiling of billions of dollars of Tamiflu. The critics of 
oseltamivir, most prominently Cochrane/ BMJ point to the dearth 
of high quality evidence. Their opponents base their opinions on 
observational data, which is less rigorous, but compelling none-
theless. At the present, clinical practice favors action i.e. the use of 
oseltamivir for both prophylaxis and treatment. The clinical deci-
sion supporting resource “UpToDate” continues to recommend 
treatment with the anti-virals as per the recommendation of the 
CDC and the IDSA. This is based on the observational study data 
that shows its effectiveness. It seems that the current consen-
sus in Hospitals is to give Tamiflu as a first line defense both for 
prophylaxis and for treatment. Although evidence shows it may 
not be as effective as we once thought, this is basically our only 
defense against influenza. In hospitalized patients with preexisting 
complications we wish to take all possible precautions. This au-
thor wishes to point out that such an approach is defensible only 
in an environment in which cost of treatment (financial and side 
effect) is not prohibitive. We wonder whether this calculus would 
be different elsewhere.
Many things can be learned from the Tamiflu controversy. Firstly, 
as demonstrated by Cochrane, one may err in assuming that 
because a paper is published in a peer reviewed journal all the 
evidence is reliable. Especially when an important decision must 
be made the data should be reviewed for accuracy, reliability of 
methods and lack of bias. Secondly, as suggested by Cochrane, the 
trustworthiness of decision making by government bodies should 
be questioned. In any situation, conflict of interest may be present. 
Thirdly, as suggested by their critics, was the Cochrane disingen-
uous in completely ignoring observational data supporting use of 
Tamiflu?  And were the Cochrane writers sensationalists in their 
conclusions and media communications?
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